Quantitative evaluation for effect of iron supplementation therapy on erythropoiesis efficiency in hemodialysis patients treated with rHuEPO

Quantitative evaluation for effect of iron supplementation therapy on erythropoiesis efficiency in hemodialysis patients treated with rHuEPO - Low dose iron supplementation therapy and rHuEPO erythropoiesis efficiency

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020700

Enrollment

100

Registered

2016-01-22

Start date

2016-01-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Maintenance hemodialysis/ Renal anemia

Interventions

Low dose iron supplementation (Fesin 20mg/week for 2 months) Standard iron supplementation (Fesin 40mg/week for 2 months)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients with maintenance hemodialysis (2) Patients with renal anemia, who are treated with rHuEPO or iron

Exclusion criteria

Exclusion criteria: (1) Patients with chronic inflammation, malignant disorder, severe congestive heart failure, respiratory organs, and liver disorder (2) Patients who are receiving dialysis modalities other than hemodialysis

Design outcomes

Primary

Measure	Time frame
(1) Hemoglobin and erythropoiesis-related indexes (2)Blood chemical examination including iron-related, inflammation, nutrition indexes (3)Required dose of rHuEPO (4)Hemodynamic parameters (1)-(4): Two-month after the start of iron administration.	—

Countries

Japan

Contacts

Public ContactTetsuya Fujikawa

Yokohama National University Center for Health Service Sciences

tftf@ynu.ac.jp045-339-3153

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026